Chemomab Therapeutics Ltd.

CMMB

US16385C1045

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
0.659 ^USD	-1.64%		-5.86%	+29.22%

Apr. 10	Transcript : Chemomab Therapeutics Ltd. - Special Call
Mar. 07	Chemomab Therapeutics Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Chemomab Therapeutics Ltd.(NasdaqCM:CMMB) added to S&P Global BMI Index

September 20, 2021 at 12:00 am EDT

Latest news about Chemomab Therapeutics Ltd.

Transcript : Chemomab Therapeutics Ltd. - Special Call	Apr. 10
Chemomab Therapeutics Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 07	CI
Chemomab Therapeutics Ltd. Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis	Jan. 30	CI
Chemomab Therapeutics Ltd. Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024	Jan. 03	CI
ADRs Advance, YPF S.A. Climbs 39.9%	Nov. 20	DJ
ADRs Advance, Missfresh Ltd. Climbs 23.3%	Nov. 17	DJ
ADRs End Lower; VNET Group Declines 26%	Nov. 16	DJ
ADRs Slump; FLJ Group Ltd. Declines 13.7%	Nov. 15	DJ
Top Midday Gainers	Nov. 15	MT
Chemomab Therapeutics Ltd. Announces U.S. Food and Drug Administration Grants CM-101 Fast Track Designation for Treatment in Adult Patients of Primary Sclerosing Cholangitis	Nov. 15	CI
Chemomab Therapeutics Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Roth MKM Starts Chemomab Therapeutics at Buy, $7 Price Target	23-10-06	MT
Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis At 2023 Roth MKM Healthcare Opportunities Conference	23-09-28	CI
Chemomab Therapeutics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis	23-06-28	CI
ADRs End Mostly Lower; Chemomab Therapeutics, Polestar Automotive Trade Actively	23-06-21	DJ
Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023	23-06-21	CI
Oppenheimer Downgrades Chemomab Therapeutics to Perform From Outperform, Removes $7 Price Target	23-06-07	MT
Chemomab Therapeutics Ltd. Appoints Nissim Darvish, MD, PhD, as Chairman of the Board Effective June 1, 2023	23-06-05	CI
Chemomab Therapeutics Announces Appointment of Sigal Fattal as Chief Financial Officer Effective June 1, 2023	23-06-05	CI
Chemomab Therapeutics Ltd. Names Adi Mor, Phd as CEO	23-06-05	CI
Transcript : Chemomab Therapeutics Ltd., Q1 2023 Earnings Call, May 11, 2023	23-05-11
Chemomab Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Oppenheimer Adjusts Chemomab Therapeutics Price Target to $7 From $12, Maintains Outperform Rating	23-04-18	MT
Sector Update: Health Care Stocks Edge Above Tuesday Intraday Lows	23-02-21	MT

Chart Chemomab Therapeutics Ltd.

Duration

Period

More charts

Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Sector

Biotechnology & Medical Research

Calendar

2024-05-09 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.659 USD

Average target price

7 USD

Spread / Average Target

+962.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CHEMOMAB THERAPEUTICS LTD.	+29.22%	9.36M
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	103B
REGENERON PHARMACEUTICALS, INC.	+1.41%	95.71B
ARGENX SE	+0.79%	22.02B
BIONTECH SE	-17.84%	20.9B
GENMAB A/S	-11.11%	17.85B
WUXI APPTEC CO., LTD.	-42.83%	16.21B
BEIGENE, LTD.	-17.63%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.86B
SAREPTA THERAPEUTICS, INC.	+32.11%	12.04B

Bio Therapeutic Drugs